SMARCA4 Mutation clinical trials at UCSF

1 research study open to eligible people

PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
open to eligible people ages 18 years and up
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
San Francisco, California and other locations

Last updated: March 7, 2025